Detalhe da pesquisa
1.
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
Oncologist
; 28(4): 351-357, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36745014
2.
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Ann Surg Oncol
; 27(4): 1180-1188, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31848819
3.
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
Oncologist
; 24(5): e196-e197, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910868
4.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Lancet Oncol
; 19(3): 310-322, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29449192
5.
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Nature
; 487(7408): 500-4, 2012 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22763439
6.
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
Ann Surg Oncol
; 24(4): 939-946, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27804026
7.
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Ophthalmology
; 124(12): 1788-1798, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28709702
8.
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Nature
; 480(7377): 387-90, 2011 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22113612
9.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Nature
; 467(7315): 596-9, 2010 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20823850
10.
Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.
Am J Dermatopathol
; 38(9): 687-9, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27541170
11.
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
Cancer
; 121(1): 60-8, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25186461
12.
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Oncologist
; 20(7): 789-97, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25956405
13.
Progression of RAS-mutant leukemia during RAF inhibitor treatment.
N Engl J Med
; 367(24): 2316-21, 2012 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23134356
14.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
N Engl J Med
; 366(3): 207-15, 2012 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22256804
15.
Immune Checkpoint Inhibitor-Associated Optic Neuritis.
Ophthalmology
; 127(11): 1585-1589, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32437864
16.
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Lancet Oncol
; 15(3): 323-32, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24508103
17.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N Engl J Med
; 364(26): 2507-16, 2011 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-21639808
18.
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
JAMA
; 311(23): 2397-405, 2014 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24938562
19.
Changing the standard of care for treating melanoma brain metastases.
Lancet Oncol
; 19(5): 589-591, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29602645
20.
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.
Cancer J
; 30(2): 48-53, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38527257